NASDAQ$RNAC
Selecta Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Cartesian Therapeutics reported financial results for Q1 2024 and provided a business update.
Cartesian Therapeutics reported cash, cash equivalents, and restricted cash of approximately $104.8 million as of March 31, 2024. Net loss was $(56.8) million, or $(10.50) per share.
- Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis on track for mid-2024.
- On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoimmune indications in 2H24.
- New headquarters expected to support scale of wholly owned, in-house cGMP manufacturing capabilities.
- Cash, cash equivalents, and restricted cash of approximately $104.8M as of March 31, 2024, expected to support planned operations into 2H 2026.
Headline financials
Revenue & EPS history
Selecta Biosciences · Revenue · Quarterly
$5.84M
Forward guidance
The Company’s cash, cash equivalents and restricted cash as of March 31, 2024 is expected to support planned operations and the development of Cartesian’s pipeline into the second half of 2026, including the planned Phase 3 trial of Descartes-08 in MG.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+0.3%
Avg return
Earnings day
-1.5%
Avg return
5 days after
+0.8%
Avg return
30 days after
36%
14 / 39 earnings
Positive
+43.0%
Q2 2022
Best reaction
-58.1%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.9% | +14.2% | — | |
| Q4 2025 | +31.7% | +7.9% | -10.2% | |
| Q3 2025 | -1.6% | -4.8% | -10.3% | |
| Q2 2025 | -6.6% | +0.4% | -5.7% | |
| Q1 2025 | -5.0% | -4.2% | +5.9% | |
| Q3 2024 | -0.5% | -18.8% | +20.5% | |
| Q2 2024 | -5.9% | -3.8% | -8.7% | |
| Q1 2024 | -5.8% | -7.6% | +57.6% | |
| Q4 2023 | -8.6% | -16.0% | -36.6% | |
| Q3 2023 | +11.7% | +11.7% | -26.6% | |
| Q2 2023 | +3.7% | +7.3% | +4.6% | |
| Q1 2023 | -6.1% | +2.6% | +11.3% | |
| Q4 2022 | -3.1% | -5.0% | -13.1% | |
| Q3 2022 | +0.6% | -4.9% | -18.4% | |
| Q2 2022 | +43.0% | +55.2% | +10.9% | |
| Q1 2022 | +7.4% | -0.6% | +10.2% | |
| Q4 2021 | -5.7% | -16.6% | -32.0% | |
| Q3 2021 | -6.1% | -8.1% | -23.5% | |
| Q2 2021 | +13.1% | +8.9% | +15.4% | |
| Q1 2021 | -0.7% | +3.7% | +65.4% | |
| Q4 2020 | +9.5% | +16.7% | +7.2% | |
| Q3 2020 | -8.2% | -8.2% | -2.7% | |
| Q2 2020 | -4.7% | -3.6% | -21.6% | |
| Q1 2020 | +1.3% | +4.2% | +17.5% | |
| Q4 2019 | -12.3% | -35.6% | -28.5% | |
| Q3 2019 | -8.4% | -9.7% | -1.3% | |
| Q2 2019 | -6.3% | -11.5% | +3.1% | |
| Q1 2019 | -4.8% | -8.4% | -9.6% | |
| Q4 2018 | +37.8% | +21.6% | +22.1% | |
| Q3 2018 | -5.0% | -2.8% | -7.4% | |
| Q2 2018 | +0.9% | -1.5% | +3.8% | |
| Q1 2018 | +1.3% | +10.4% | +16.1% | |
| Q4 2017 | -16.6% | -22.8% | +7.4% | |
| Q3 2017 | -58.1% | -59.9% | -56.0% | |
| Q2 2017 | -1.4% | -7.1% | +3.8% | |
| Q1 2017 | -2.1% | +3.2% | +9.3% | |
| Q4 2016 | +16.1% | +18.9% | +5.7% | |
| Q3 2016 | +27.2% | +17.9% | +20.3% | |
| Q2 2016 | -4.6% | -1.7% | +25.4% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro